Zobrazeno 1 - 10
of 99
pro vyhledávání: '"Marie‐Claude Viaud Massuard"'
Autor:
Camille Blouet, Stéphanie Letast, Thomas Robert, Stéphane Bach, Noël Pinaud, Nicolas Joubert, Marie-Claude Viaud-Massuard, Jean Guillon, Cédric Logé, Caroline Denevault-Sabourin
Publikováno v:
Molbank, Vol 2023, Iss 4, p M1735 (2023)
Potassium 6-oxo-7,13,16,22-tetraazatetracyclo[12.6.2.18,12.017,21]tricosa-1(20),8(23),9,11,14,16,18,21-octaen-2-yne-15-carboxylate was synthesized through a multi-step pathway, starting from commercially available 3-iodo-1,2-phenylenediamine. Structu
Externí odkaz:
https://doaj.org/article/eb3c8596c9f24290a70b6f4142e78806
Autor:
Ofelia Feuillâtre, Camille Gély, Steve Huvelle, Christine B. Baltus, Ludovic Juen, Nicolas Joubert, Audrey Desgranges, Marie-Claude Viaud-Massuard, Camille Martin
Publikováno v:
ACS Omega, Vol 5, Iss 3, Pp 1557-1565 (2020)
Externí odkaz:
https://doaj.org/article/ee9481fb6507457dbd19485a634fd2f0
Autor:
Nicolas Aubrey, Valérie Gouilleux-Gruart, Christine Dhommée, Julie Mariot, Fanny Boursin, Nicolas Albrecht, Cécile Bergua, Cécile Croix, Mäelle Gilotin, Eloi Haudebourg, Catherine Horiot, Laetitia Matthias, Caroline Mouline, Laurie Lajoie, Audrey Munos, Gilles Ferry, Marie-Claude Viaud-Massuard, Gilles Thibault, Florence Velge-Roussel
Publikováno v:
Antibodies, Vol 11, Iss 3, p 54 (2022)
Bispecific antibodies (BsAbs) represent an important advance in innovative therapeutic strategies. Among the countless formats of BsAbs, fusion with molecules such as anticalins linked to a monoclonal antibody (mAb), represents an easy and low-cost w
Externí odkaz:
https://doaj.org/article/c53d720fbba84a0fb3de25e6b0f595e5
Autor:
Francesco De Pascali, Mohammed Akli Ayoub, Riccardo Benevelli, Silvia Sposini, Jordan Lehoux, Nathalie Gallay, Pauline Raynaud, Flavie Landomiel, Frédéric Jean-Alphonse, Christophe Gauthier, Lucie P. Pellissier, Pascale Crépieux, Anne Poupon, Asuka Inoue, Nicolas Joubert, Marie-Claude Viaud-Massuard, Livio Casarini, Manuela Simoni, Aylin C. Hanyaloglu, Selva G. Nataraja, Henry N. Yu, Stephen S. Palmer, Romain Yvinec, Eric Reiter
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 18, p 9850 (2021)
Follicle-stimulating hormone receptor (FSHR) plays a key role in reproduction through the activation of multiple signaling pathways. Low molecular weight (LMW) ligands composed of biased agonist properties are highly valuable tools to decipher comple
Externí odkaz:
https://doaj.org/article/f144abbebe294986baabcf655018a84f
Autor:
Bruno Oyallon, Marie Brachet-Botineau, Cédric Logé, Thomas Robert, Stéphane Bach, Sajida Ibrahim, William Raoul, Cécile Croix, Pascal Berthelot, Jean Guillon, Noël Pinaud, Fabrice Gouilleux, Marie-Claude Viaud-Massuard, Caroline Denevault-Sabourin
Publikováno v:
Molecules, Vol 26, Iss 4, p 867 (2021)
Proviral integration site for Moloney murine leukemia virus (Pim)-1/2 kinase overexpression has been identified in a variety of hematologic (e.g., multiple myeloma or acute myeloid leukemia (AML)) and solid (e.g., colorectal carcinoma) tumors, playin
Externí odkaz:
https://doaj.org/article/a0e34a16b11a4b37ba7ae3360def4efc
Autor:
Ludovic Juen, Christine B. Baltus, Camille Gély, Thibault Kervarrec, Ofelia Feuillâtre, Audrey Desgranges, Marie-Claude Viaud-Massuard, Camille Martin
Publikováno v:
Bioconjugate Chemistry. 33:418-426
With three clinically approved antibody-drug conjugates targeting HER2, this target is clearly identified to be of interest in oncology. Moreover, the advent of new bioconjugation technologies producing site-specific homogenous conjugates led to the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd8f2817c573aa1d1aa1fa4d9f39cfe0
https://doi.org/10.1021/acs.bioconjchem.2c00015
https://doi.org/10.1021/acs.bioconjchem.2c00015
Autor:
Audrey Desgranges, Camille Martin, Camille Gély, Marie-Claude Viaud-Massuard, Ludovic Juen, Ofelia Feuillâtre, Christine B. Baltus
Publikováno v:
Bioconjugate Chemistry. 32:595-606
To overcome stability and heterogeneity issues of antibody-drug conjugates (ADCs) produced with existing bioconjugation technologies incorporating a maleimide motif, we developed McSAF Inside, a new technology based on a trifunctionalized di(bromomet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c31313d0989be50aca9224db74205ce
https://doi.org/10.1021/acs.bioconjchem.1c00058
https://doi.org/10.1021/acs.bioconjchem.1c00058
Autor:
Ludovic Juen, Camille Gély, Audrey Desgranges, Ofelia Feuillâtre, Nicolas Joubert, Camille Martin, Christine B. Baltus, Marie-Claude Viaud-Massuard, Steve Huvelle
Publikováno v:
ACS Omega
ACS Omega, Vol 5, Iss 3, Pp 1557-1565 (2020)
ACS Omega, Vol 5, Iss 3, Pp 1557-1565 (2020)
Antibody–drug conjugates (ADCs) are the spearhead of targeted therapies. According to the technology used, the conjugation of a cytotoxic drug to an antibody can produce suboptimal heterogeneous species, impacting the overall efficacy. Herein, we d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8eca9a84065672450d88c66b3dac2ce2
https://doi.org/10.1021/acsomega.9b03510
https://doi.org/10.1021/acsomega.9b03510
Autor:
Clara, Esnault, David, Schrama, Roland, Houben, Serge, Guyétant, Audrey, Desgranges, Camille, Martin, Patricia, Berthon, Marie-Claude, Viaud-Massuard, Antoine, Touzé, Thibault, Kervarrec, Mahtab, Samimi
Publikováno v:
Cancers. 14(3)
Antibody-drug conjugates (ADCs) are an emerging class of therapeutics, with twelve FDA- and EMA-approved drugs for hematological and solid cancers. Such drugs consist in a monoclonal antibody linked to a cytotoxic agent, allowing a specific cytotoxic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::06491980758d5e9a45a616621aa38655
https://pubmed.ncbi.nlm.nih.gov/35159045
https://pubmed.ncbi.nlm.nih.gov/35159045
Autor:
Clara Esnault, David Schrama, Roland Houben, Serge Guyétant, Audrey Desgranges, Camille Martin, Patricia Berthon, Marie-Claude Viaud-Massuard, Antoine Touzé, Thibault Kervarrec, Mahtab Samimi
Publikováno v:
Cancers, Vol 14, Iss 778, p 778 (2022)
Antibody–drug conjugates (ADCs) are an emerging class of therapeutics, with twelve FDA- and EMA-approved drugs for hematological and solid cancers. Such drugs consist in a monoclonal antibody linked to a cytotoxic agent, allowing a specific cytotox
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::70a6351cb01f05ad7d71d8c8aeb77e38
https://doi.org/10.3390/cancers14030778
https://doi.org/10.3390/cancers14030778
